awmsg logo



darunavir (Prezista®)


Reference No. 101

Publication date:
07/09/2007


Appraisal information

darunavir (Prezista®) film-coated tablet


Company: Janssen-Cilag Ltd
BNF category: Infections
NMG meeting date: 12/07/2007
AWMSG meeting date: 15/08/2007
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 0907
Ministerial ratification: 29/08/2007

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Darunavir (Prezista®) should be recommended within NHS Wales for the treatment of human immunodeficiency virus (HIV-1) infection in highly pre-treated adults who have failed more than one regimen containing a protease inhibitor (PI), and where resistance profiling suggests it is appropriate. Use should be in accordance with the British HIV Association (BHIVA) guidance. Darunavir (Prezista®) is not presently recommended for shared care.
Final Appraisal Recommendation (FAR)
Download